Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Boston Scientific Begins Clinical Trial For Next-Generation Nitinol Stent To Treat Iliac Artery Disease
Boston Scientific Corporation (NYSE: BSX) announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company"s EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease that impacts a patient"s lower extremities. The first U.S. patient was enrolled on May 14 by Nicolas W. Shammas, M.D., at Trinity Terrace Park Hospital in Bettendorf, Iowa.
generic viagra online
Americans Who Say They Are In Excellent Health Enjoy More "Special" Birthday Celebrations
As the official sponsor of birthdays, the American Cancer Society announced new survey results that show people who say they are in excellent health enjoy better birthdays. The online survey of 2,002 U.S. adults, which demonstrated a strong link between health and attitudes about birthdays, revealed that people who say they are in excellent health are more likely to consider birthdays special and exciting events. In addition, people who say they are in excellent health are nearly twice as likely to love celebrating birthdays, generally consider them fun and feel more special on their birthday than people who say they are in poor health.
News of the day
Safer Transportation Of A Child With Special Needs
A new study by researchers from the Automotive Safety Program at Riley Hospital for Children and Indiana University School of Medicine published online July 13, 2009 in the journal Pediatrics reports that the parents of children with special health care needs are doing a good job with the selection of the appropriate child car seat but still need help in using it correctly.
Sexual Health

Kinex Pharmaceuticals To Present At ASCO 2009 Annual Meeting

Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled "Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies." The presentation will provide data from this multi-center Phase 1 trial that utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with refractory solid tumors. Patients who responded to treatment will be highlighted. This presentation was designated as Best of ASCO(R) which features high-impact abstracts from the 2009 ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today. This information has been selected to be presented at meetings in the US and internationally because it highlights the latest scientific findings in primary disease sites and practice-changing advances in cancer prevention and treatment. Kinex Pharmaceuticals is a drug discovery and development company that is focused on next generation drugs to treat cancer and immuno-inflammatory diseases. The Company has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control. Kinex Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009